

Prophylactic Mastectomy, Prophylactic Oophorectomy, And Prophylactic Hysterectomy

Issue Date: October 25, 1993
Authority: [32 CFR 199.4\(c\)\(2\)](#)

1.0 CPT¹ PROCEDURE CODES

19300 - 19307, 58150 - 58294, 58541 - 58554, 58661, **58720**, 58940 - 58956

2.0 DESCRIPTION

2.1 Prophylactic mastectomy is an extirpative procedure (usually simple or total mastectomy) which removes all breast tissue which would be otherwise subject to breast carcinoma. Carefully selected indications have been developed for prophylactic mastectomy and are included in this policy.

2.2 Prophylactic oophorectomy is removal of the ovaries before development of cancerous cells. Carefully selected indications have been developed for prophylactic oophorectomy and are included in this policy.

2.3 Prophylactic hysterectomy is removal of the uterus before development of cancerous cells. Carefully selected indications have been developed for prophylactic hysterectomy and are included in this policy.

3.0 POLICY

3.1 Bilateral prophylactic mastectomies are covered for patients at increased risk of developing breast carcinoma who have one or more of the following:

3.1.1 Atypical hyperplasia of lobular or ductal origin confirmed on biopsy; or

3.1.2 A history of Breast Cancer (BRCA) in multiple first-degree relatives and/or multiple successive generations of family members with breast and/or ovarian cancer (Family Cancer Syndrome). A positive BRCA genetic test is not necessary; or

3.1.3 Fibronodular, dense breasts which are mammographically and/or clinically difficult to evaluate and the patient presents with either of the above (or both) clinical presentations.

¹ CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

Prophylactic Mastectomy, Prophylactic Oophorectomy, And Prophylactic Hysterectomy

3.2 Unilateral prophylactic mastectomies are covered when the contralateral breast has been diagnosed with cancer for patients with:

3.2.1 Diffuse microcalcifications in the remaining breast, especially when ductal in-situ carcinoma has been diagnosed in the contralateral breast; or

3.2.2 Lobular carcinoma in-situ; or

3.2.3 Large breast and/or ptotic, dense or disproportionately-sized breast that are difficult to evaluate mammographically and clinically; or

3.2.4 In whom observational surveillance is elected for lobular carcinoma in-situ and the patient develops either invasive lobular or ductal carcinoma; or

3.2.5 A history of breast cancer in multiple first-degree relatives and/or multiple successive generations of family members with breast and/or ovarian cancer (Family Cancer Syndrome). A positive BRCA genetic test is not necessary; or

3.3 Prophylactic oophorectomy is covered for women who meet any of the following criteria:

3.3.1 Women who have been diagnosed with an hereditary ovarian cancer syndrome based on a family pedigree constructed by an authorized provider competent in determining the presence of an autosomal dominant inheritance pattern; or

3.3.2 Women with a personal history of steroid hormone receptor-positive breast cancer; or

3.3.3 Women with a personal history of breast cancer and at least one first degree relative (mother, sister, daughter) with a history of ovarian cancer; or

3.3.4 Women who have two or more first degree relatives with a a history of breast or ovarian cancer; or

3.3.5 Women with one first degree relative and one or more second degree relative (grandmother, aunt, or niece) with ovarian cancer.

3.3.6 Some families have pedigrees that are very small, and therefore have only one first degree relative with ovarian cancer or young-onset breast, colon, or endometrial cancer that may suggest increased risk for ovarian cancer. These individuals may also be considered for prophylactic oophorectomy. Effective January 1, 2006.

3.4 Prophylactic hysterectomy is covered:

3.4.1 For women who are about to undergo or are undergoing tamoxifen therapy.

3.4.2 For women who have been diagnosed with Hereditary Nonpolyposis Colorectal Cancer (HNPCC) or are found to be carriers of HNPCC-associated mutations.

3.5 Benefits will only be allowed for subcutaneous mastectomies performed as an alternative treatment for benign breast diseases if the individual is not at high risk of breast cancer.

4.0 EXCLUSION

Subcutaneous mastectomy, a procedure that is not extirpative, fails to remove all breast tissue. Therefore, subcutaneous mastectomy is not effective as prophylactic assurance against breast cancer in high risk indications, nor is subcutaneous mastectomy a cancer treatment. Therefore, benefits will not be allowed for subcutaneous mastectomy in the prevention of breast carcinoma.

- END -

